IP Library Granted Patent US 7,628,807
Granted Patent B2
US 7,628,807 · App. 10/982,356 · Granted Dec 8, 2009

Stent for delivering a therapeutic agent having increased body tissue contact surface

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,628,807
App. No.
10/982,356
Granted
Dec 8, 2009
Kind
B2
Abstract

A stent for implantation in a body lumen is described comprising at least one strut having an inner surface, an outer surface, a first side surface disposed between the inner surface and the outer surface, and a second side surface disposed between the inner surface and the outer surface; wherein the first side surface and the second side surface converge toward one another in the direction of the outer surface; and a coating comprising a therapeutic agent disposed on at least a portion of a surface of the strut.

Claims (28)

1. A stent for implantation in a body lumen comprising:

(a) at least one strut having an inner surface, an outer surface, a first side surface disposed between the inner surface and the outer surface, and a second side surface disposed between the inner surface and the outer surface;

wherein the first side surface and the second side surface converge toward one another in the direction of the outer surface;

a coating comprising a first therapeutic agent to encourage endothelial cell growth disposed only on the inner surface of the strut; and

a second therapeutic agent that is different from the first therapeutic agent, the second therapeutic agent disposed on at least a portion of the first side surface or second side surface.

2. The stent of claim 1 wherein the second therapeutic agent is further disposed on at least a portion of the outer surface.

3. The stent of claim 1 wherein the second therapeutic agent is disposed on at least a portion of the first side surface and at least a portion of the second side surface.

4. The stent of claim 1 wherein the strut comprises a cross-section having a substantially trapezoidal shape.

5. The stent of claim 4 wherein first side surface and the second side surface form the sides of the substantially trapezoidal shape.

6. The stent of claim 1 wherein the outer surface is substantially curved.

7. The stent of claim 1 wherein the strut comprises a cross-section having a substantially triangular shape.

8. The stent of claim 7 wherein first side surface and the second side surface form the sides of the substantially triangular shape.

9. The stent of claim 1 wherein at least one of the first or second therapeutic agents comprises paclitaxel, an analog of paclitaxel or a derivative of paclitaxel.

10. The stent of claim 1 wherein at least one of the first or second therapeutic agents comprise a macrolide selected from the group consisting of sirolimus, tacrolimus, or everolimus.

11. The stent of claim 1 wherein the coating further comprises a polymeric material.

12. The stent of claim 11 wherein the polymeric material incorporates at least the first therapeutic agent.

13. The stent of claim 1 wherein the stent is an intravascular stent.

14. The stent of claim 1 wherein the strut further comprises a third side surface disposed between the inner surface and the outer surface and in contact with the inner surface, and a fourth side surface disposed between the inner surface and the outer surface and in contact with the inner surface.

15. The stent of claim 1 wherein the first therapeutic agent comprises antibodies CD33 or CD34.

16. A stent for implantation in a body lumen comprising:

(a) at least one strut having an inner surface, an outer surface, a first side surface disposed between the inner surface and the outer surface, and a second side surface disposed between the inner surface and the outer surface;

wherein the first side surface and the second side surface converge toward one another in the direction of the outer surface;

(b) a first coating comprising a first therapeutic agent and a first polymeric material disposed on at least a portion of the outer surface, a portion of the first side surface, and a portion of the second side surface; and

(c) a second coating comprising a second therapeutic agent and a second polymeric material disposed only on the inner surface:

wherein the first therapeutic agent has a different therapeutic purpose than that on the second therapeutic agent; and

wherein the purpose of the second therapeutic agent is to encourage endothelial cell growth.

17. The stent of claim 16 wherein at least one of the first or second therapeutic agents comprise paclitaxel, an analog of paclitaxel or a derivative of paclitaxel.

18. The stent of claim 16 wherein at least one of the first or second therapeutic agents comprise a macrolide selected from the group consisting of sirolimus, tacrolimus, or everolimus.

Assignments (2)
CHANGE OF NAME Recorded Nov 6, 2006
From: SCIMED LIFE SYSTEMS, INC.
To: BOSTON SCIENTIFIC SCIMED, INC.
Reel/Frame 018505/0868 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 4, 2004
From: FLANAGAN, AIDEN
To: SCIMED LIFE SYSTEMS, INC.
Reel/Frame 015968/0463 →